RECENT
09/17/2018
Q&A with Dr. Corey A. Carter, President and CEO of EpicentRx Inc. developing “smart” oncolytic virus therapies in combining immuno-oncology agents that activate the human immune system against cancer with minimal toxicity for patients
Interview – CEOCFO Magazine September 17, 2018 Issue
08/09/2018
Radioprotectors: Defensive Weapons In The War On Cancer
“RRx-001 use as radioprotector”
Authors: Scott Caroen, Corey Carter, Bryan Oronsky
05/02/2018
EpicentRx Announces First Ever Treatment of Cancer Patient with Personalized, Custom-Made Viral Vaccines
08/19/2015
EpicentRx Announces Publication of Phase 1 Trial Results for the Anti-Cancer Agent, RRx-001, in Lancet Oncology
05/02/2018
First Patient Treated With Next-Generation Immunotherapy at UC Cincinnati